COMPANY PROFILE

Fuse Oncology

Innovative UI/UX design solutions enhancing functionality, ease of use, and aesthetics for web and application interfaces

Boone, United StatesFounded 2021Biotech & Life Sciences

Valuation $50–100M Last recorded · 2023

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Fuse Oncology

Fuse Oncology is a technology-driven company specializing in the development of advanced UI/UX design solutions aimed at improving the functionality, ease of use, and aesthetics of web and application interfaces. The company serves a diverse range of clients, including healthcare providers, tech startups, and enterprise-level businesses, primarily operating in the healthcare and technology markets. Fuse Oncology's business model revolves around offering bespoke design services tailored to meet the specific needs of its clients, thereby ensuring a high level of customer satisfaction and repeat business. The company generates revenue through project-based contracts and long-term partnerships, leveraging its expertise to provide innovative and visually appealing solutions that enhance user experience.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: Boone, United States
Employees: 27
Open positions: 1
Dealroom signal: 36.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: SaaS
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Apr 2023	$8.9M	$36M	Undisclosed	↗
SEEDEquity / VC	Feb 2022	$0	—	First Launch Capital Fund	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth
2026
2025
2024
2023
2022		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Fuse Oncology website traffic

Latest recorded traffic for Fuse Oncology is 2.5K monthly website visits, up 25% over the last three months. Fuse Oncology's team declined 3.6% over the past year.

Latest monthly visits2.5K 3-month web change+25% 1-year team growth-3.6%

Monthly website visitsJan 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Software Engineer in Test (SDET)/QA LeadGreensboro, Guilford County, North Carolina, United States · Backend Development · Aug 6, 2026

1 distinct opening shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational	44	$217M	$700M
STSolve TherapeuticsTargeted cancer therapies enhancing safety and precision	San Diego, United States	Operational
EPEpitopeaTransatlantic cancer immunotherapeutics company	Montreal, Canada	Operational
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
ITIntegra TherapeuticsIntegra Therapeutics is a biotech company developing next-generation gene writing tools to cure genetic diseases	Barcelona, Spain	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
STStratus TherapeuticsDeveloping off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases	Natick, United States	Operational
JTJuvena TherapeuticsA biopharmaceutical platform which is discovering novel protein-based therapeutics	Palo Alto, United States	Operational